A Novel Therapeutic System for the Treatment of Occult Prostate Cancer

Abstract

The goal of this research was to investigate the efficacy and mechanisms of H5BVIFN-beta, a novel immunotherapeutic agent, against prostate cancer in animal models. The purpose of study in the first year was to determine the efficacy of H5BVIFN-beta therapy in suppressing the progression of tumors of TRAMP-L5 murine prostate cancer cells in syngeneic immune competent mice. The authors found that intratumoral delivery of H5BVIFN-beta significantly inhibited the growth of both orthotopic and ecotopic lesions of TRAMP-L5 cells by bout 50 percent. The H5BVIFN-beta therapy moderately but significantly prolonged the survival of tumor-bearing mice, but it could not eradicate TRAMP-L5 tumors in either the orthotopic or ecotopic model.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2005
Accession Number
ADA438273

Entities

People

  • Shongyun Dong

Organizations

  • University of Cincinnati

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Blood
  • Cancer
  • Cells
  • Immunity
  • Immunomodulation
  • Immunotherapy
  • Interferon
  • Lymph Nodes
  • Lymphatic System
  • Lymphocytes
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • T Lymphocytes
  • Therapy
  • Universities

Fields of Study

  • Medicine

Readers

  • Medical Imaging.
  • Oncology
  • Prostate Cancer Biology.